<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591990</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200033</org_study_id>
    <secondary_id>2020-001620-33</secondary_id>
    <nct_id>NCT04591990</nct_id>
  </id_info>
  <brief_title>HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome</brief_title>
  <acronym>HYVAPRESS</acronym>
  <official_title>HYdrocortisone and VAsopressin in Post-REsuscitation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate the superiority of arginine-vasopressin (AVP) and&#xD;
      hydrocortisone compared with norepinephrine regarding day-30 survival and neurological&#xD;
      recovery in post-cardiac arrest patients with hemodynamic failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients successfully resuscitated who got restoration of spontaneous circulation (ROSC)&#xD;
      after cardiopulmonary resuscitation (CPR), the course is usually marked by a&#xD;
      post-resuscitation syndrome including multiple organ failures of various intensity and anoxic&#xD;
      brain damage. The cardiocirculatory failure usually dominates the clinical picture, and it&#xD;
      often leads to multiorgan failure. This hemodynamic failure is multifactorial, including at&#xD;
      various levels vasoplegia, myocardial dysfunction, endotoxin release and adrenal dysfunction&#xD;
      and is at least partly related to a hormonal defect that could be counteracted by hormonal&#xD;
      supplementation. Such a substitutive opotherapy by hydrocortisone and AVP could improve&#xD;
      hemodynamic failure and decrease overall mortality in this setting.&#xD;
&#xD;
      This trial is a superiority multicentric trial and patients will be randomized in a 1:1:1:1&#xD;
      ratio using an electronic CRF.&#xD;
&#xD;
      Investigational medicinal products:&#xD;
&#xD;
      - Arginin-vasopressin or AVP (REVERPLEG) The solution for infusion is prepared by diluting 40&#xD;
      I.U. REVERPLEG® with sodium chloride 9 mg/ml (0.9%) solution. The total volume after dilution&#xD;
      should be 50 ml (equivalent to 0.8 I.U. AVP per ml).&#xD;
&#xD;
      AVP will be administered according to mean arterial pressure to target a 65mmHg blood&#xD;
      pressure for max 3 days.&#xD;
&#xD;
      - HYDROCORTISONE HEMISUCCINATE Vials with lyophilisate (100mg hydrocortisone) are provided by&#xD;
      SERB laboratory. Hydrocortisone hemisuccinate will be administered as a 50mg intravenous&#xD;
      bolus every 6 hours after an initial dose of 100mg, for 7 consecutive days. Stop of treatment&#xD;
      by hydrocortisone will be performed without tapering.&#xD;
&#xD;
      Comparator treatment: placebos.&#xD;
&#xD;
      17 ICU centers in France will participate to this study targetting 380 patient's enrollment&#xD;
      in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological outcome</measure>
    <time_frame>at day-30</time_frame>
    <description>The primary endpoint will be the good neurological outcome at day-30. This will be evaluated using the Glasgow Outcome Scale (GOS, addendum 18.5.1) dichotomized as follow: good neurological outcome for categories 4 and 5 and poor neurological outcome or death for categories 3, 2 and 1. The GOS will be obtained at day-30 from an in-hospital visit if the patient is still hospitalized or from telephone contact with patients, relatives or general practitioners.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>at day-30</time_frame>
    <description>Vital status at day-30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality attributed to irreversible hemodynamic failure</measure>
    <time_frame>at day-30</time_frame>
    <description>Time to irreversible cardiovascular failure defined as death in pharmacologically uncontrollable hypotension (mean arterial blood pressure &lt; 60 mmHg) despite maximal ICU care, or withdrawal of care based on same, as previously defined (Witten L, Resuscitation 2019).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality attributed to neurological withdrawal of care</measure>
    <time_frame>at day-30</time_frame>
    <description>Time to neurological withdrawal of care. Withdrawal of care will be based on expectations of a poor neurological recovery based on most recent guidelines (Sandroni C, ICM 2015).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality attributed to comorbid withdrawal of care</measure>
    <time_frame>at day-30</time_frame>
    <description>Time to comorbid withdrawal of care. Comorbid withdrawal of care or refusal of life-sustaining therapy based on the expectation of a poor quality of life. This may be related to a preexisting or newly discovered terminal illness or other serious medical condition (e.g. dementia or cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day-30 brain death</measure>
    <time_frame>at day-30</time_frame>
    <description>Time to brain death (according to French legislation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality attributed to recurrent cardiac arrest</measure>
    <time_frame>at day-30</time_frame>
    <description>Time to recurrent cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other causes</measure>
    <time_frame>at day-30</time_frame>
    <description>Proportion of patients dead from a cause not listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological recovery at day-30</measure>
    <time_frame>at day-30</time_frame>
    <description>Glasgow outcome score - extended at day-30. This score will be evaluated similarly to the primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain damage</measure>
    <time_frame>at 48 hours and at 72hours</time_frame>
    <description>Neuron-specific enolase (NSE) blood level measured 48 and 72 hours after CA</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Postresuscitation Syndrome</condition>
  <arm_group>
    <arm_group_label>AVP + placebo hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REVERPLEG® 40 IU/2mL+ Placebo of hydrocortisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo AVP + hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo of REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVP + hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo AVP + placebo hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo of REVERPLEG® 40 IU/2mL + placebo of hydrocortisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of AVP</intervention_name>
    <description>Administration of AVP</description>
    <arm_group_label>AVP + hydrocortisone</arm_group_label>
    <arm_group_label>AVP + placebo hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of placebo AVP</intervention_name>
    <description>Administration of placebo AVP</description>
    <arm_group_label>placebo AVP + hydrocortisone</arm_group_label>
    <arm_group_label>placebo AVP + placebo hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of placebo hydrocortisone</intervention_name>
    <description>Administration of placebo hydrocortisone</description>
    <arm_group_label>AVP + placebo hydrocortisone</arm_group_label>
    <arm_group_label>placebo AVP + placebo hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of hydrocortisone</intervention_name>
    <description>Administration of hydrocortisone</description>
    <arm_group_label>AVP + hydrocortisone</arm_group_label>
    <arm_group_label>placebo AVP + hydrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt;18y)&#xD;
&#xD;
          -  Cardiac arrest (in-hospital or out-of-hospital) with sustained ROSC (&gt; 30 minutes)&#xD;
             admitted to the ICU&#xD;
&#xD;
          -  Post-resuscitation shock defined as arterial hypotension (SAP &lt; 90 mmHg or MAP &lt; 65&#xD;
             mmHg) unresponsive to adequate fluid loading, which occurred within the first 24 hours&#xD;
             after ROSC and requiring norepinephrine/epinephrine continuous infusion at a dose&#xD;
             greater or equal to 0.2µg/kg/min for at least 3 hours&#xD;
&#xD;
          -  A maximal delay between the start of norepinephrine infusion and randomization of 9&#xD;
             hours&#xD;
&#xD;
          -  Informed written consent of the patient or a legally authorized close relative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence for a traumatic or a neurological cause of cardiac arrest&#xD;
&#xD;
          -  Shock due to uncontrolled haemorrhage&#xD;
&#xD;
          -  Previously known adrenal insufficiency&#xD;
&#xD;
          -  Limitation of life-sustaining therapies&#xD;
&#xD;
          -  Ongoing treatment by any steroids, whatever the dose&#xD;
&#xD;
          -  Ongoing extra-corporeal circulatory assistance&#xD;
&#xD;
          -  Gastrointestinal bleeding in the past 6 weeks&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Participation in another interventional study involving human participants or being in&#xD;
             the exclusion period at the end of a previous study involving human participants, if&#xD;
             applicable&#xD;
&#xD;
          -  Hypersensitivity to arginin-vasopressin and to its excipients&#xD;
&#xD;
          -  Hypersensitivity to hydrocortisone and to its excipients&#xD;
&#xD;
          -  Legal protection (i.e. incompetence to provide consent, guardianship, curator or&#xD;
             incarceration)&#xD;
&#xD;
          -  No affiliation with the French health care system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume GERI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Intensive Care Unit, Ambroise Paré Hospital, APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain CARIOU, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Intensive Care Unit, Cochin Hospital, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume GERI, MD, PhD</last_name>
    <phone>+33 (0) 1 71 16 77 33</phone>
    <email>guillaume.geri@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, Ambroise Paré Hospital, APHP</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Witten L, Gardner R, Holmberg MJ, Wiberg S, Moskowitz A, Mehta S, Grossestreuer AV, Yankama T, Donnino MW, Berg KM. Reasons for death in patients successfully resuscitated from out-of-hospital and in-hospital cardiac arrest. Resuscitation. 2019 Mar;136:93-99. doi: 10.1016/j.resuscitation.2019.01.031. Epub 2019 Jan 30.</citation>
    <PMID>30710595</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intensive care</keyword>
  <keyword>hydrocortisone</keyword>
  <keyword>vasopressin</keyword>
  <keyword>post-resuscitation syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

